OpenAI buys Orchestra Bio to push deeper into drug discovery
The ChatGPT maker is folding the biotech software start-up into Rosalind, its AI model for life sciences research, whose customers already include Moderna and Novo Nordisk.
Key points
- OpenAI has acquired Orchestra Bio, which builds AI agents for biotech companies.
- Orchestra's team and technology will join Rosalind, OpenAI's life sciences model.
- Orchestra had raised about $20 million from backers including Andreessen Horowitz.
OpenAI has bought Orchestra Bio, a small start-up that builds AI agents for biotech companies, as the maker of ChatGPT pushes further into the business of discovering new medicines.
OpenAI announced the deal on its website overnight. It did not disclose the price.
Orchestra, founded about four years ago, makes software agents that take on the operational grind of drug discovery: keeping track of research budgets, for instance, or sorting out clashes in clinical trial schedules. It had reportedly raised around $20 million by 2025, from investors including Andreessen Horowitz, Atria and 8VC.
Where Orchestra fits
OpenAI said Orchestra’s team and technology will be folded into Rosalind, its AI model built for life sciences research, and into Rosalind Workbench, a tool meant to help scientists plan experiments and make sense of the results. The company says the vaccine maker Moderna and the Danish drugmaker Novo Nordisk, best known for its weight-loss medicines, are already Rosalind customers.
The deal is the latest sign of how the biggest AI labs are moving beyond general chatbots into software made for specific industries, with pharmaceuticals high on the list. OpenAI and its rival Anthropic are both building tools aimed at large companies in such sectors.
That shift worries many smaller start-ups, which fear that the labs could launch a competing feature at any moment and wipe out their business. For Orchestra, the outcome was different: rather than being squeezed out of the market, it has been absorbed by one of the companies it might otherwise have had to fight.